Phanes Therapeutics Gains FDA Fast Track for Spevatamig
San Diego, California, August 14, 2026 Phanes Therapeutics, Inc., a clinical-stage biotechnology company focused on immuno-oncology drug discovery and...
Merck
Advertisement
Merck FDA Accepts ENFLONSIA sBLA for Second RSV Season
RAHWAY, N.J., August 6, 2026 Merck announced that the U.S. Food and Drug Administration (FDA) has accepted a supplemental...
Merck & Co., Inc. Expands Global Access to Once-Monthly Alimatravir
RAHWAY, N.J., July 24, 2026 Merck has announced an ambitious global access strategy for alimatravir (MK-8527), its investigational once-monthly...
Gilead Sciences and Merck & Co. Deliver Positive ISLEND Phase 3 Results
FOSTER CITY, Calif. & RAHWAY, N.J., July 22, 2026 Gilead Sciences and Merck announced detailed results from the Phase...
LEO Pharma Reports Positive Phase 2 Tralokinumab Results
BALLERUP, Denmark, July 9, 2026 LEO Pharma A/S has announced positive results from the Phase 2 TRAPEDS-1 clinical trial...
Advertisements
Merck Announces Expanded FDA Approval for Keytruda in MIBC
SILVER SPRING, Maryland, July 10, 2026 Merck has received U.S. Food and Drug Administration (FDA) approval for Keytruda® (pembrolizumab)...
Merck’s CAPVAXIVE Wins FDA Approval for High-Risk Children
RAHWAY, N.J., June 18, 2026 Merck announced that the U.S. Food and Drug Administration (FDA) has approved an expanded...
Protillion Biosciences Partners With Merck on AI Drug Discovery
CARLSBAD, Calif., June 16, 2026 Protillion Biosciences has announced a significant multi-target drug discovery collaboration and license agreement with...
Merck and Gilead End KEYNOTE-D46 Study Update
RAHWAY, N.J. and FOSTER CITY, Calif., June 8, 2026 Merck (NYSE: MRK) and Gilead Sciences (Nasdaq: GILD) announced the...
Merck’s KEYTRUDA and Padcev Combination Shows Strong Survival Benefit Ahead of EU Approval
RAHWAY, New Jersey, May 24, 2026 Merck announced that the European Medicines Agency’s Committee for Medicinal Products for Human...
Advertisement
